KURA
Price
$7.73Alerts
Change
+$0.16 (+2.11%)
Updated
Nov 11 closing price
Capitalization
646.74M
106 days until earnings call
Intraday BUY SELL Signals
ZBIO
Price
$28.70Alerts
Change
+$0.12 (+0.42%)
Updated
Nov 11 closing price
Capitalization
1.84B
Intraday BUY SELL Signals
Interact to see
Advertisement

KURA vs ZBIO

KURA vs ZBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KURA vs. ZBIO commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KURA is a Hold and ZBIO is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for KURA with price predictions
Nov 10, 2026

KURA's RSI Indicator climbs out of oversold territory

The RSI Oscillator for KURA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +11.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where KURA advanced for three days, in 211 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

KURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KURA as a result. In 70 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for KURA turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 39 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for KURA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. KURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.354) is normal, around the industry mean (3.498). P/E Ratio (-2.157) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.821) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for ZBIO with price predictions
Nov 10, 2026

ZBIO's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ZBIO turned positive on October 20, 2026. Looking at past instances where ZBIO's MACD turned positive, the stock continued to rise in 18 of 19 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ZBIO as a result. In 39 of 45 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

Following a +1.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZBIO advanced for three days, in 117 of 133 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

ZBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 20 of 27 cases where ZBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for ZBIO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ZBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.454) is normal, around the industry mean (3.498). P/E Ratio (-2.935) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1666.667) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
KURA vs ZBIO: Fundamental Ratings
KURA
ZBIO
OUTLOOK RATING
1..100
1131
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
7948
P/E GROWTH RATING
1..100
1498
SEASONALITY SCORE
1..100
6570

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KURA's Valuation (81) in the Biotechnology industry is in the same range as ZBIO (87) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.

KURA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ZBIO (100) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.

KURA's SMR Rating (99) in the Biotechnology industry is in the same range as ZBIO (100) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.

ZBIO's Price Growth Rating (48) in the null industry is in the same range as KURA (79) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to KURA’s over the last 12 months.

KURA's P/E Growth Rating (14) in the Biotechnology industry is significantly better than the same rating for ZBIO (98) in the null industry. This means that KURA’s stock grew significantly faster than ZBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KURAZBIO
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 2 days ago
88%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (KURA: $7.57 vs. ZBIO: $28.58)
Brand notoriety: KURA and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KURA: 132% vs. ZBIO: 44%
Market capitalization -- KURA: $646.74M vs. ZBIO: $1.84B
KURA [@Biotechnology] is valued at $646.74M. ZBIO’s [@Biotechnology] market capitalization is $1.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KURA’s FA Score shows that 1 FA rating(s) are green while ZBIO’s FA Score has 0 green FA rating(s).

  • KURA’s FA Score: 1 green, 4 red.
  • ZBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, both KURA and ZBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KURA’s TA Score shows that 4 TA indicator(s) are bullish while ZBIO’s TA Score has 4 bullish TA indicator(s).

  • KURA’s TA Score: 4 bullish, 4 bearish.
  • ZBIO’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ZBIO is a better buy in the short-term than KURA.

Price Growth

KURA (@Biotechnology) experienced а -23.38% price change this week, while ZBIO (@Biotechnology) price change was +0.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

KURA is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ZBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with REPL. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZBIO
1D Price
Change %
ZBIO100%
+0.04%
REPL - ZBIO
41%
Loosely correlated
+4.58%
KURA - ZBIO
39%
Loosely correlated
N/A
RZLT - ZBIO
37%
Loosely correlated
+4.09%
PVLA - ZBIO
37%
Loosely correlated
-3.08%
NTLA - ZBIO
36%
Loosely correlated
-7.76%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LANV0.700.01
+1.54%
Lanvin Group Holdings Limited
SNN30.92-0.13
-0.42%
Smith & Nephew plc
OIS8.33-0.17
-2.00%
OIL States International
CHR1.24-0.05
-3.88%
Cheer Holding Inc.
ASAN9.59-0.43
-4.29%
Asana